title: Mean platelet volume in patients with prolactinoma.
abstract: OBJECTIVE
  Prolactin is a multifunctional pituitary hormone. The effect of prolactin on platelet activation is not well understood. Prolactinomas are the most common type of pituitary adenomas, and they are medically responsive to dopamine agonists. Mean platelet volume (MPV) is a marker of platelet function and activation. The aim of this study was to evaluate MPV values before and 6 months of cabergoline treatment when normoprolactinemia was achieved.
  
  
  METHODS
  A total of 101 newly diagnosed prolactinoma patients and 102 healthy control subjects were included in the study. Patients with hematological disorders that affect MPV and those on medications were excluded. Prolactin, platelet count and MPV levels were recorded before and 6 months after the initiation of cabergoline treatment (0.5 to 1 mg, two times a week).
  
  
  RESULTS
  There was no significant difference in platelet count and MPV before and after 6 months of treatment with cabergoline in patients with prolactinoma compared with the control group (p > 0.05).
  
  
  CONCLUSIONS
  Our results showed that MPV, a marker of platelet function, was unchanged in patients with prolactinoma.
authors.affiliation: Ataturk Training and Research Hospital, Department of Endocrinology and Metabolism, Ankara, Turkey.
authors.forename: Abbas Ali
authors.initials: AA
authors.lastname: Tam
authors.affiliation: Ataturk Training and Research Hospital, Department of Endocrinology and Metabolism, Ankara, Turkey.
authors.forename: Cafer
authors.initials: C
authors.lastname: Kaya
authors.affiliation: Ataturk Training and Research Hospital, Department of Endocrinology and Metabolism, Ankara, Turkey.
authors.forename: Hüsniye
authors.initials: H
authors.lastname: Başer
authors.affiliation: Yıldırım Beyazıt University, Department of Endocrinology and Metabolism, Ankara, Turkey.
authors.forename: Reyhan
authors.initials: R
authors.lastname: Ersoy
authors.affiliation: Yıldırım Beyazıt University, Department of Endocrinology and Metabolism, Ankara, Turkey.
authors.forename: Bekir
authors.initials: B
authors.lastname: Çakır
mesh_terms: D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood; D000077465:Cabergoline; D016022:Case-Control Studies; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D063847:Mean Platelet Volume; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000097:blood* / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000097:blood* / Q000188:drug therapy*; D012016:Reference Values; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D018491:Dopamine Agonists; D004873:Ergolines; D011388:Prolactin; D000077465:Cabergoline